SANOFI ADR

NASDAQ: SNY (Sanofi)

Kemas kini terakhir: semalam, 12:20PM

49.95

-0.88 (-1.73%)

  • 1H -1.73%
  • 5H -1.03%
  • 1B -1.79%
  • 6B 8.85%
  • Tahun Ke Tarikh 3.65%
  • 1T 5.62%
  • 5T -1.27%
Penutupan Terdahulu 50.83
Buka 49.46
Jumlah Dagangan 1,379,688
Purata Dagangan (3B) 2,700,485
Modal Pasaran 121,631,744,000
Harga / Pendapatan (P/E TTM) 17.53
Harga / Pendapatan (P/E Ke hadapan) 10.85
Harga / Jualan (P/S) 2.46
Harga / Buku (P/B) 1.46
Julat 52 Minggu
45.80 (-8%) — 60.12 (20%)
Tarikh Pendapatan 31 Jul 2025
Hasil Dividen (DY TTM) 4.43%
Margin Keuntungan 13.95%
Margin Operasi (TTM) 20.78%
EPS Cair (TTM) 2.85
Pertumbuhan Hasil Suku Tahunan (YOY) -4.60%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 65.20%
Jumlah Hutang/Ekuiti (D/E MRQ) 23.01%
Nisbah Semasa (MRQ) 1.46
Aliran Tunai Operasi (OCF TTM) 9.08 B
Aliran Tunai Bebas Leveraj (LFCF TTM) -4.94 B
Pulangan Atas Aset (ROA TTM) 4.28%
Pulangan Atas Ekuiti (ROE TTM) 7.30%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menurun Bercampur
Drug Manufacturers - General (Global) Menurun Bercampur
Stok Sanofi Menaik Menaik

AISkor Stockmoo

0.3
Konsensus Penganalisis 3.5
Aktiviti Orang Dalam NA
Volatiliti Harga -1.0
Purata Bergerak Teknikal 1.0
Osilator Teknikal -2.5
Purata 0.25

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
SNY 122 B 4.43% 17.53 1.46
AZN 226 B 2.13% 29.27 6.19
AMGN 157 B 3.17% 26.31 25.15
GILD 124 B 3.13% 20.97 7.30
GRFS 6 B - 28.00 0.910
BIIB 17 B - 11.68 1.14

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Core
% Dimiliki oleh Institusi 10.49%

Pemilikan

Nama Tarikh Syer Dipegang
Mondrian Investment Partners Ltd 31 Dec 2024 3,453,122
66.0066.0063.0063.0060.0060.0057.0057.0054.0054.00Harga Sasaran MedianQ1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25
Julat 52 Minggu
45.80 (-8%) — 60.12 (20%)
Median 65.00 (30.13%)
Jumlah 1 Pegang
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Goldman Sachs 21 Mar 2025 65.00 (30.13%) Pegang 56.90

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
09 Jun 2025 Pengumuman Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
09 Jun 2025 Pengumuman Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
09 Jun 2025 CNBC FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
09 Jun 2025 Pengumuman Sanofi: Information concerning the total number of voting rights and shares - May 2025
05 Jun 2025 Pengumuman Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
03 Jun 2025 Pengumuman Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
03 Jun 2025 Pengumuman Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
03 Jun 2025 Pengumuman Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
03 Jun 2025 Pengumuman Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
02 Jun 2025 Pengumuman Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
02 Jun 2025 Pengumuman Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
02 Jun 2025 Pengumuman Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
30 May 2025 Pengumuman Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
30 May 2025 Pengumuman Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
29 May 2025 Pengumuman Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
29 May 2025 Pengumuman Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
22 May 2025 Pengumuman Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence
21 May 2025 Pengumuman Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
21 May 2025 Pengumuman Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
21 May 2025 Pengumuman Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
20 May 2025 Pengumuman Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD)
15 May 2025 Pengumuman Sanofi: Information concerning the total number of voting rights and shares - April 2025
14 May 2025 Pengumuman Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing
02 May 2025 Pengumuman Sanofi: Information concerning the total number of voting rights and shares - March 2025
30 Apr 2025 Pengumuman Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
30 Apr 2025 Pengumuman Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
30 Apr 2025 Pengumuman Press Release: Annual General Meeting of April 30, 2025
30 Apr 2025 Pengumuman Press Release: Annual General Meeting of April 30, 2025
29 Apr 2025 Pengumuman Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
29 Apr 2025 Pengumuman Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
24 Apr 2025 Pengumuman Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
24 Apr 2025 Pengumuman Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
18 Apr 2025 Pengumuman Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
18 Apr 2025 Pengumuman Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
15 Apr 2025 Pengumuman Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement
15 Apr 2025 Pengumuman Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
15 Apr 2025 Pengumuman Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
08 Apr 2025 Pengumuman Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
08 Apr 2025 Pengumuman Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
03 Apr 2025 Pengumuman Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
03 Apr 2025 Pengumuman Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
03 Apr 2025 Pengumuman Sanofi: Information concerning the total number of voting rights and shares - February 2025
28 Mar 2025 Pengumuman Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
28 Mar 2025 Pengumuman Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
28 Mar 2025 Pengumuman Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
28 Mar 2025 Pengumuman Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
26 Mar 2025 Pengumuman Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
26 Mar 2025 Pengumuman Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
25 Mar 2025 Pengumuman Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
25 Mar 2025 Pengumuman Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
24 Mar 2025 Pengumuman Press Release: Availability of the Q1 2025 Aide mémoire
24 Mar 2025 Pengumuman Press Release: Availability of the Q1 2025 Aide mémoire
20 Mar 2025 Pengumuman Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
20 Mar 2025 Pengumuman Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Papar semua
Hasil Dividen (DY TTM) 4.43%
Purata Hasil Dividen 5T 4.78%
Nisbah Pembayaran 75.37%
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
09 May 2025 15 Apr 2025 12 Jun 2025 2.212154 Tunai
09 May 2024 26 Mar 2024 06 Jun 2024 2.037356 Tunai
09 May 2024 26 Mar 2024 06 Jun 2024 2.0369079 Tunai
30 May 2023 - 23 Jun 2023 1.9000852 Tunai
26 May 2022 - 27 Jun 2022 0.2971788 Tunai
04 May 2022 20 Apr 2022 31 May 2022 1.7967514 Tunai
03 May 2021 23 Mar 2021 26 May 2021 1.906064 Tunai
30 Apr 2020 05 Mar 2020 26 May 2020 1.6993994 Tunai
07 May 2019 - 31 May 2019 1.722322 Tunai
09 May 2018 07 Feb 2018 04 Jun 2018 1.860874 Tunai
11 May 2017 16 Feb 2017 07 Jun 2017 1.577088 Tunai
05 May 2016 19 Feb 2016 01 Jun 2016 1.630252 Tunai
06 May 2015 25 Feb 2015 02 Jun 2015 1.618087 Tunai
17 May 2010 12 Feb 2010 14 Jun 2010 1.62732 Tunai
04 Jun 2007 05 Mar 2007 03 Jul 2007 1.14537 Tunai
02 Jun 2006 06 Mar 2006 03 Jul 2006 0.912 Tunai
02 Jun 2005 01 Mar 2005 01 Jul 2005 0.7993 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 2.21 1 4.43
2024 4.07 2 8.45
2023 1.90 1 3.82
2022 2.09 2 4.32
2021 1.91 1 3.81
2020 1.70 1 3.50
2019 1.72 1 3.43
2018 1.86 1 4.29
2017 1.58 1 3.67
2016 1.63 1 4.03
2015 1.62 1 3.79
2010 1.63 1 5.05
2007 1.15 1 2.52
2006 0.912 1 1.98
2005 0.799 1 1.82
Papar semua
52.0552.0551.0651.0650.0650.0649.0749.0748.0848.08Jun 4Jun 4Jun 5Jun 5Jun 6Jun 6Jun 9Jun 9Jun 10Jun 10Jun 11Jun 11Jun 12Jun 12Jun 13Jun 13

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.2000.200-0.000-0.000-0.200-0.200-0.400-0.400-0.600-0.600MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda